Helus Pharma cites currency switch, share consolidation and Nasdaq move as key Q1 FY2027 factors for Cybin
HELP•Management commentary focused on corporate changes in Q1 FY2027
For the three months ended June 30, 2026, management commentary centered on corporate changes rather than operating drivers or earnings factors.
- Presentation currency shifted to USD to better match expense mix and improve comparability with peers, affecting how results are reported.
- U.S. listing moved to Nasdaq under ticker HELP, alongside a shift to operating under the Helus Pharma business name.
- Share consolidation of 1-for-38 was completed in 2024, with per-share figures retrospectively restated across periods.
